<?xml version='1.0' encoding='utf-8'?>
<document id="11468938"><sentence text="A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide."><entity charOffset="94-110" id="DDI-PubMed.11468938.s1.e0" text="cyclophosphamide" /><entity charOffset="115-123" id="DDI-PubMed.11468938.s1.e1" text="thioTEPA" /><entity charOffset="149-165" id="DDI-PubMed.11468938.s1.e2" text="cyclophosphamide" /><pair ddi="false" e1="DDI-PubMed.11468938.s1.e0" e2="DDI-PubMed.11468938.s1.e0" /><pair ddi="false" e1="DDI-PubMed.11468938.s1.e0" e2="DDI-PubMed.11468938.s1.e1" /><pair ddi="false" e1="DDI-PubMed.11468938.s1.e0" e2="DDI-PubMed.11468938.s1.e2" /><pair ddi="false" e1="DDI-PubMed.11468938.s1.e1" e2="DDI-PubMed.11468938.s1.e1" /><pair ddi="false" e1="DDI-PubMed.11468938.s1.e1" e2="DDI-PubMed.11468938.s1.e2" /></sentence><sentence text="Cyclophosphamide (CP) is widely used in high-dose chemotherapy regimens in combination with thioTEPA"><entity charOffset="0-16" id="DDI-PubMed.11468938.s2.e0" text="Cyclophosphamide" /><entity charOffset="18-20" id="DDI-PubMed.11468938.s2.e1" text="CP" /><entity charOffset="92-100" id="DDI-PubMed.11468938.s2.e2" text="thioTEPA" /><pair ddi="false" e1="DDI-PubMed.11468938.s2.e0" e2="DDI-PubMed.11468938.s2.e0" /><pair ddi="false" e1="DDI-PubMed.11468938.s2.e0" e2="DDI-PubMed.11468938.s2.e1" /><pair ddi="false" e1="DDI-PubMed.11468938.s2.e0" e2="DDI-PubMed.11468938.s2.e2" /><pair ddi="false" e1="DDI-PubMed.11468938.s2.e1" e2="DDI-PubMed.11468938.s2.e1" /><pair ddi="false" e1="DDI-PubMed.11468938.s2.e1" e2="DDI-PubMed.11468938.s2.e2" /></sentence><sentence text=" CP is a prodrug and is activated by cytochrome P450 to 4-hydroxycyclophosphamide (HCP) which yields the final cytotoxic metabolite phosphoramide mustard (PM)"><entity charOffset="56-81" id="DDI-PubMed.11468938.s3.e0" text="4-hydroxycyclophosphamide" /><entity charOffset="83-86" id="DDI-PubMed.11468938.s3.e1" text="HCP" /><entity charOffset="1-3" id="DDI-PubMed.11468938.s3.e2" text="CP" /><entity charOffset="84-86" id="DDI-PubMed.11468938.s3.e3" text="CP" /><pair ddi="false" e1="DDI-PubMed.11468938.s3.e2" e2="DDI-PubMed.11468938.s3.e2" /><pair ddi="false" e1="DDI-PubMed.11468938.s3.e2" e2="DDI-PubMed.11468938.s3.e0" /><pair ddi="false" e1="DDI-PubMed.11468938.s3.e2" e2="DDI-PubMed.11468938.s3.e1" /><pair ddi="false" e1="DDI-PubMed.11468938.s3.e2" e2="DDI-PubMed.11468938.s3.e3" /><pair ddi="false" e1="DDI-PubMed.11468938.s3.e0" e2="DDI-PubMed.11468938.s3.e0" /><pair ddi="false" e1="DDI-PubMed.11468938.s3.e0" e2="DDI-PubMed.11468938.s3.e1" /><pair ddi="false" e1="DDI-PubMed.11468938.s3.e0" e2="DDI-PubMed.11468938.s3.e3" /><pair ddi="false" e1="DDI-PubMed.11468938.s3.e1" e2="DDI-PubMed.11468938.s3.e1" /><pair ddi="false" e1="DDI-PubMed.11468938.s3.e1" e2="DDI-PubMed.11468938.s3.e3" /></sentence><sentence text=" The metabolism of CP into HCP exhibits autoinduction but is inhibited by thioTEPA"><entity charOffset="19-20" id="DDI-PubMed.11468938.s4.e0" text="CP" /><entity charOffset="28-29" id="DDI-PubMed.11468938.s4.e1" text="CP" /><entity charOffset="27-28" id="DDI-PubMed.11468938.s4.e2" text="HCP" /><pair ddi="false" e1="DDI-PubMed.11468938.s4.e0" e2="DDI-PubMed.11468938.s4.e0" /><pair ddi="false" e1="DDI-PubMed.11468938.s4.e0" e2="DDI-PubMed.11468938.s4.e2" /><pair ddi="false" e1="DDI-PubMed.11468938.s4.e0" e2="DDI-PubMed.11468938.s4.e1" /><pair ddi="false" e1="DDI-PubMed.11468938.s4.e2" e2="DDI-PubMed.11468938.s4.e2" /><pair ddi="false" e1="DDI-PubMed.11468938.s4.e2" e2="DDI-PubMed.11468938.s4.e1" /></sentence><sentence text=" The aim of this study was to develop a population pharmacokinetic model for the bioactivation route of CP incorporating the phenomena of both autoinduction and the drug-drug interaction between CP and thioTEPA"><entity charOffset="104-106" id="DDI-PubMed.11468938.s5.e0" text="CP" /><entity charOffset="195-197" id="DDI-PubMed.11468938.s5.e1" text="CP" /><pair ddi="false" e1="DDI-PubMed.11468938.s5.e0" e2="DDI-PubMed.11468938.s5.e0" /><pair ddi="false" e1="DDI-PubMed.11468938.s5.e0" e2="DDI-PubMed.11468938.s5.e1" /></sentence><sentence text=" Plasma samples were collected from 34 patients who received high-dose CP, thioTEPA and carboplatin in short infusions during 4 consecutive days"><entity charOffset="75-83" id="DDI-PubMed.11468938.s6.e0" text="thioTEPA" /><entity charOffset="88-99" id="DDI-PubMed.11468938.s6.e1" text="carboplatin" /><entity charOffset="71-81" id="DDI-PubMed.11468938.s6.e2" text="CP" /><pair ddi="false" e1="DDI-PubMed.11468938.s6.e2" e2="DDI-PubMed.11468938.s6.e2" /><pair ddi="false" e1="DDI-PubMed.11468938.s6.e2" e2="DDI-PubMed.11468938.s6.e0" /><pair ddi="false" e1="DDI-PubMed.11468938.s6.e2" e2="DDI-PubMed.11468938.s6.e1" /><pair ddi="false" e1="DDI-PubMed.11468938.s6.e0" e2="DDI-PubMed.11468938.s6.e0" /><pair ddi="false" e1="DDI-PubMed.11468938.s6.e0" e2="DDI-PubMed.11468938.s6.e1" /></sentence><sentence text=" Elimination of CP was described by a noninducible route and an inducible route leading to HCP"><entity charOffset="16-17" id="DDI-PubMed.11468938.s7.e0" text="CP" /><entity charOffset="92-93" id="DDI-PubMed.11468938.s7.e1" text="CP" /><entity charOffset="91-92" id="DDI-PubMed.11468938.s7.e2" text="HCP" /><pair ddi="false" e1="DDI-PubMed.11468938.s7.e0" e2="DDI-PubMed.11468938.s7.e0" /><pair ddi="false" e1="DDI-PubMed.11468938.s7.e0" e2="DDI-PubMed.11468938.s7.e2" /><pair ddi="false" e1="DDI-PubMed.11468938.s7.e0" e2="DDI-PubMed.11468938.s7.e1" /><pair ddi="false" e1="DDI-PubMed.11468938.s7.e2" e2="DDI-PubMed.11468938.s7.e2" /><pair ddi="false" e1="DDI-PubMed.11468938.s7.e2" e2="DDI-PubMed.11468938.s7.e1" /></sentence><sentence text=" The latter route was mediated by a hypothetical amount of enzyme" /><sentence text=" Autoinduction leads to a zero-order increase in amount of this enzyme during treatment" /><sentence text=" Inhibition by thioTEPA was modeled as a reversible, competitive, concentration-dependent inhibition" /><sentence text=" PM pharmacokinetics were described by first-order formation from HCP and first-order elimination"><entity charOffset="67-69" id="DDI-PubMed.11468938.s11.e0" text="CP" /><entity charOffset="66-68" id="DDI-PubMed.11468938.s11.e1" text="HCP" /><pair ddi="false" e1="DDI-PubMed.11468938.s11.e1" e2="DDI-PubMed.11468938.s11.e1" /><pair ddi="false" e1="DDI-PubMed.11468938.s11.e1" e2="DDI-PubMed.11468938.s11.e0" /></sentence><sentence text=" The final models for CP, HCP, and PM provided an adequate fit of the experimental data"><entity charOffset="26-29" id="DDI-PubMed.11468938.s12.e0" text="HCP" /><entity charOffset="22-24" id="DDI-PubMed.11468938.s12.e1" text="CP" /><entity charOffset="27-29" id="DDI-PubMed.11468938.s12.e2" text="CP" /><pair ddi="false" e1="DDI-PubMed.11468938.s12.e1" e2="DDI-PubMed.11468938.s12.e1" /><pair ddi="false" e1="DDI-PubMed.11468938.s12.e1" e2="DDI-PubMed.11468938.s12.e0" /><pair ddi="false" e1="DDI-PubMed.11468938.s12.e1" e2="DDI-PubMed.11468938.s12.e2" /><pair ddi="false" e1="DDI-PubMed.11468938.s12.e0" e2="DDI-PubMed.11468938.s12.e0" /><pair ddi="false" e1="DDI-PubMed.11468938.s12.e0" e2="DDI-PubMed.11468938.s12.e2" /></sentence><sentence text=" The volume of distribution, noninducible and initial inducible clearances of CP were 31"><entity charOffset="78-79" id="DDI-PubMed.11468938.s13.e0" text="CP" /></sentence><sentence text="0 L, 1" /><sentence text="58 L/hr and 4" /><sentence text="76 L/hr, respectively" /><sentence text=" The enzyme amount increased with a zero-order rate constant of 0" /><sentence text="041 amount * hr-1" /><sentence text=" After each thioTEPA infusion, however, approximately 80% of the enzyme was inhibited"><entity charOffset="12-20" id="DDI-PubMed.11468938.s19.e0" text="thioTEPA" /></sentence><sentence text=" This inhibition was reversible with a half-life of 6" /><sentence text="5 hr" /><sentence text=" The formation and elimination rate constants of PM were 1" /><sentence text="58 and 0" /><sentence text="338 hr-1, respectively" /><sentence text=" The developed model enabled the assessment of the complex pharmacokinetics of CP in combination with thio TEPA"><entity charOffset="102-111" id="DDI-PubMed.11468938.s25.e0" text="thio TEPA" /><entity charOffset="79-87" id="DDI-PubMed.11468938.s25.e1" text="CP" /><pair ddi="false" e1="DDI-PubMed.11468938.s25.e1" e2="DDI-PubMed.11468938.s25.e1" /><pair ddi="false" e1="DDI-PubMed.11468938.s25.e1" e2="DDI-PubMed.11468938.s25.e0" /></sentence><sentence text=" This model provided an adequate description of enzyme induction and inhibition and can be used for treatment optimization in this combination" /><sentence text="" /></document>